US4247466A - Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid - Google Patents

Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid Download PDF

Info

Publication number
US4247466A
US4247466A US06/054,748 US5474879A US4247466A US 4247466 A US4247466 A US 4247466A US 5474879 A US5474879 A US 5474879A US 4247466 A US4247466 A US 4247466A
Authority
US
United States
Prior art keywords
biphenylyl
furanone
dihydro
hydroxy
biphenylylcarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/054,748
Inventor
Fortunato S. Chiccarelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US06/054,748 priority Critical patent/US4247466A/en
Application granted granted Critical
Publication of US4247466A publication Critical patent/US4247466A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D315/00—Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups C07D303/00 - C07D313/00

Definitions

  • U.S. Pat. No. 3,966,960 to Ellenbogen et al. is to the use of 3-(4-biphenylcarbonyl)propionic acid as an inhibitor of platelet aggregation.
  • U.S. Pat. No. 3,784,704 to Cohen et al. describes the use and preparation of 4-biphenyl acetic acid in the amelioration of pain.
  • This invention is concerned with new compounds of the formula: ##STR1## wherein R 1 , R 2 and R 3 are each selected from the group comprising hydrogen and hydroxy and where R 2 and R 3 include both the cis and trans configurations.
  • This invention is also concerned with methods of treating inflammation and platelet aggregation, by the administration of compounds of the formula: ##STR2## wherein R 1 , R 2 and R 3 are as described above.
  • these compounds include the following:
  • the compound 5-(4-biphenylyl)dihydro-2-(3H)-furanone may be prepared by treating 3-(4-biphenylylcarbonyl)-propionic acid in basic medium with sodium borohydride. The addition of acetic acid precipitates a solid which is again treated with sodium borohydride in basic medium, and precipitated with glacial acetic acid giving 4-(4-biphenylyl)-4-hydroxybutyric acid. This product is treated with a mineral acid and then neutralized with sodium acetate giving the desired product.
  • the compound Dihydro-5-(4'-hydroxy-4-biphenylyl)-2(3H)-furanone may be prepared by treating 4'-methoxy- ⁇ -oxo-4-biphenylbutyric acid with hydrogen bromide in acid to produce 4'-hydroxy- ⁇ -oxo-4-biphenylbutyric acid. This in turn is treated with sodium borohydride as described above and then purified with organic solvents to produce the desired product.
  • the other compounds of this invention may be prepared as metabolites of 3-(4-biphenylylcarbonyl)propionic acid in warm-blooded animals.
  • the compounds of this invention may be incorporated with excipients and used, for example, in the form of tablets, dragees, capsules, liquids, elixirs, emulsions, suspensions, syrups, chocolate candy, wafers, chewing gum and the like.
  • Such compositions and preparations should contain at least 0.1% of active ingredient.
  • the percentage in the compositions and preparations may, of course, be varied, and may conveniently be between about 2% and 60% or more of the weight of the unit.
  • the amount of active component in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained. This dosage can also be obtained by the use of sustained release preparations.
  • Preferred compositions or preparations according to the present invention are prepared so that a dosage unit form contains between about one and 250 mg. of active component.
  • Tablets, pills, dragees and the like may contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; a disintegrating agent such as corn starch, potato starch, alginic acid or the like; a lubricant such as stearic acid, magnesium stearate, talc or the like; a sweetening agent such as sucaryl or saccharin may be added, as well as a flavoring such as peppermint, oil of wintergreen or cherry flavoring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • a disintegrating agent such as corn starch, potato starch, alginic acid or the like
  • a lubricant such as stearic acid, magnesium stearate, talc or the like
  • a sweetening agent such as sucaryl or saccharin may be added, as well as a flavoring such as peppermint, oil of wintergreen or cherry flavor
  • the compounds of the present invention are active as inhibitors of platelet aggregation.
  • the compounds were tested essentially according to the method of G. V. R. Born, Nature, No. 4832, pp. 927-929 (1962) and J. R. O'Brien, J. Clin. Path., 15, 446-452 (1962).
  • Various concentrations of the test compounds were added in vitro to human platelet rich plasma.
  • Collagen was added at a final concentration of 500 mcg./ml. to induce platelet aggregation.
  • Inhibition of platelet aggregation was determined by direct comparison of the optical density of the plasma treated with the test compound and a control. The result of such a test on a representative compound of this invention appears in Table I.
  • the compounds of the present invention are active as anti-inflammatory agents.
  • the compounds were tested to determine their effect on conditions which result in inflammation by measuring the effect on ultraviolet induced erythema in guinea pigs.
  • Albino guinea pigs were depilitated on their flanks, the evening before testing, with a standard mixture of barium sulfite and gum acacia.
  • groups of 4 guinea pigs were dosed by gavage one hour (-1 hour) to ultraviolet exposure. At zero hour they were restrained in a plastic container which allows exposure of three circular spots. They were then exposed to ultraviolet irradiation from a "Hanovia" Kromayer lamp, model 10, for 60 seconds.
  • the degree of erythema for each of the three sites was assessed according to the following scoring system.
  • a 10.3 g. portion of 3-(4-biphenylylcarbonyl)propionic acid in 8 ml. of 6 N NaOH is treated with 15 g. of sodium borohydride and stirred for 2 hours.
  • the cloudy solution is treated carefully over a 30 minute period with 25 ml. of glacial acetic acid producing a colorless precipitate.
  • the solid is collected by filtration, washed with water and dried.
  • a mixture of a 9 g. portion of this solid, 7.5 ml. of 6 N NaOH and 15 g. of sodium borohydride in 2 liters of water is stirred for 2 hours.
  • the mixture is filtered and the filtrate is treated with glacial acetic acid giving 5 g. of 4-(4-biphenylyl)-4-hydroxybutyric acid.
  • a 2.0 g. portion of the above product is added to 320 ml. of water.
  • a 10 ml. portion of 1 N NaOH is added.
  • a 3 g. portion of sodium borohydride is added and the mixture is stirred at room temperature overnight.
  • the mixture is cooled in ice and 12 ml. of glacial acetic acid is added.
  • the gelatinous precipitate is filtered through diatomaceous earth and washed with ether.
  • the ether is evaporated giving a solid which is treated with water and filtered, giving a solid.
  • the solid is triturated with benzene and the solid is recovered. This solid is dissolved in a small amount of ethyl acetate, benzene is added and the mixture is stored overnight in a chill room.
  • the solid is recovered by filtration and air dried.
  • the mother liquor crop (0.45 g.) is refluxed overnight in 20 ml. of xylene giving a solid which is crystallized from ethanol treated with activated charcoal giving the final product, m.p. 176.5°-181° C.
  • the column support is acid washed and methanol rinsed Celite® No. 545.
  • the column is 1.5 ⁇ 45 cm.
  • the solvent system is heptane:ethyl acetate:methanol:water:acetic acid (300:200:80:20:1.5).
  • a 20 g. portion of the Celite is mixed with 10 ml. of the lower phase of the solvent system.
  • the column is packed with 0.5 g. increments of the wet column support after placing a glass wool plug in the bottom.
  • the packed column is about 35 cm. long.
  • a 100 ml. sample of the cumulative 24 hour urine from the dogs is heated with 5 N hydrochloric acid for 30 minutes in a boiling water bath. After cooling, the solution is extracted with a mixture of chloroform:ether (8:3). The solvent extract is evaporated under nitrogen and the residue is mixed with 5.0 ml. of lower phase and 10 g. of Celite and charged on the column. The column is eluted with upper phase. Fractions of 7.0 ml are collected and radioactivity is measured in either a Beckman LS-250 Liquid Scintillation Spectrometer or a Nuclear-Chicago, Mark I Liquid Scintillation Spectrometer. The desired metabolites are located by thin-layer chromatography and identified by ultraviolet, mass spectrometer, nuclear magnetic resonance and infrared absorption patterns.
  • guinea pigs are derived as metabolic products from guinea pigs.
  • Nineteen normal guinea pigs from the Lederle colony are used. Their weight range is 290-340 g.
  • the guinea pigs are fasted overnight before dosing. Drinking water and food are available throughout the test period.
  • the guinea pigs receive a single oral dose of 100 mg. of 14 C-3-(4-biphenylylcarbonyl)propionic acid sodium salt per kg. of body weight, administered as a clear aqueous solution.
  • the guinea pigs are maintained individually in metabolism cages.
  • the urine samples are collected as 24 hour cumulative samples in containers surrounded by dry ice and then stored in a deep freeze.
  • a 40 ml. combined sample of the cumulative 24 hour urine from the guinea pigs is heated with 20 ml. of 5N-hydrochloric acid for 45 minutes in a boiling water bath. The mixture is cooled and extracted three times with a mixture of chloroform:ether (8:3). The solvent is evaporated under nitrogen. The residue is mixed with 1.0 ml. of the lower phase of the solvent system and 2.0 g. of Celite. The column is eluted with upper phase. Fractions of 3.0 ml. are collected and measured for radioactivity. The desired metabolites are located by thin-layer chromatography and identified by mass spectrometer, nuclear magnetic resonance and infrared absorption patterns.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of lactone metabolites of 3-(4-Biphenylylcarbonyl)propionic acid useful as anti-inflammatory and anti-platelet aggregation agents.

Description

BACKGROUND OF THE INVENTION
This invention is concerned with the preparation and use of antithrombotic and anti-inflammatory drugs. Some of the prior examples of related compounds will now be considered. U.S. Pat. No. 3,966,978 to Ellenbogen et al. discloses the use of 4-biphenylacetic acid in the amelioration of blood platelet aggregation. U.S. Pat. No. 3,784,701 to Tomcufcik et al. discloses a group of anti-inflammatory drugs, substituted benzoylpropionic acids, including a biphenyl which is a starting material of some of the compounds of the invention.
U.S. Pat. No. 3,966,960 to Ellenbogen et al. is to the use of 3-(4-biphenylcarbonyl)propionic acid as an inhibitor of platelet aggregation. U.S. Pat. No. 3,784,704 to Cohen et al. describes the use and preparation of 4-biphenyl acetic acid in the amelioration of pain.
U.S. Pat. No. 3,969,402 to Adams et al. discloses the preparation and use of 2-(hydroxy substituted-4-biphenylyl)propionic acids as anti-inflammatory agents.
British Pat. No. 1,390,091 describes the preparation and use of 5-(4-biphenylyl)-2-hydro-2-(3H)-furanone. The activity of this compound is indicated as "antiphlogistic" and inhibitory toward "the aggregation of thromocytes".
Finally, an article by H. Yoshizawa, Y. Tada, T. Naruke and M. Mizumura; Basic Pharmacology and Therapeutics, 2, No. 11, Dec. 15, 1974, pp. 31-40 describes 3-(4-biphenylylcarbonyl)propionic acid and derivatives.
SUMMARY OF THE INVENTION
This invention is concerned with new compounds of the formula: ##STR1## wherein R1, R2 and R3 are each selected from the group comprising hydrogen and hydroxy and where R2 and R3 include both the cis and trans configurations.
This invention is also concerned with methods of treating inflammation and platelet aggregation, by the administration of compounds of the formula: ##STR2## wherein R1, R2 and R3 are as described above.
Specifically, these compounds include the following:
5-(4-Biphenylyl)dihydro-2-(3H)-furanone, a compound disclosed in British Pat. No. 1,390,091;
Dihydro-5-(4'-Hydroxy-4-biphenylyl)-2(3H)-furanone;
5-(4-Biphenylyl)dihydro-4-hydroxy-cis-2(3H)-furanone;
5-(4-Biphenylyl)dihydro-4-hydroxy-trans-2(3H)-furanone;
5-(4-Biphenylyl)dihydro-3-hydroxy-cis-2(3H)-furanone;
5-(4-Biphenylyl)dihydro-3α-hydroxy-trans-2(3H)-furanone.
DESCRIPTION OF THE INVENTION
The compound 5-(4-biphenylyl)dihydro-2-(3H)-furanone may be prepared by treating 3-(4-biphenylylcarbonyl)-propionic acid in basic medium with sodium borohydride. The addition of acetic acid precipitates a solid which is again treated with sodium borohydride in basic medium, and precipitated with glacial acetic acid giving 4-(4-biphenylyl)-4-hydroxybutyric acid. This product is treated with a mineral acid and then neutralized with sodium acetate giving the desired product.
The compound Dihydro-5-(4'-hydroxy-4-biphenylyl)-2(3H)-furanone may be prepared by treating 4'-methoxy-γ-oxo-4-biphenylbutyric acid with hydrogen bromide in acid to produce 4'-hydroxy-γ-oxo-4-biphenylbutyric acid. This in turn is treated with sodium borohydride as described above and then purified with organic solvents to produce the desired product.
The other compounds of this invention may be prepared as metabolites of 3-(4-biphenylylcarbonyl)propionic acid in warm-blooded animals.
For therapeutic administration, the compounds of this invention may be incorporated with excipients and used, for example, in the form of tablets, dragees, capsules, liquids, elixirs, emulsions, suspensions, syrups, chocolate candy, wafers, chewing gum and the like. Such compositions and preparations should contain at least 0.1% of active ingredient. The percentage in the compositions and preparations may, of course, be varied, and may conveniently be between about 2% and 60% or more of the weight of the unit. The amount of active component in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained. This dosage can also be obtained by the use of sustained release preparations. Preferred compositions or preparations according to the present invention are prepared so that a dosage unit form contains between about one and 250 mg. of active component.
Tablets, pills, dragees and the like may contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; a disintegrating agent such as corn starch, potato starch, alginic acid or the like; a lubricant such as stearic acid, magnesium stearate, talc or the like; a sweetening agent such as sucaryl or saccharin may be added, as well as a flavoring such as peppermint, oil of wintergreen or cherry flavoring.
The compounds of the present invention are active as inhibitors of platelet aggregation.
The compounds were tested essentially according to the method of G. V. R. Born, Nature, No. 4832, pp. 927-929 (1962) and J. R. O'Brien, J. Clin. Path., 15, 446-452 (1962). Various concentrations of the test compounds were added in vitro to human platelet rich plasma. Collagen was added at a final concentration of 500 mcg./ml. to induce platelet aggregation. Inhibition of platelet aggregation was determined by direct comparison of the optical density of the plasma treated with the test compound and a control. The result of such a test on a representative compound of this invention appears in Table I.
              TABLE I                                                     
______________________________________                                    
 Compound        Concentration mcg/ml                                     
                                 Result                                   
______________________________________                                    
Dihydro 5-(4'-hydroxy-4-bi-                                               
phenylyl)-2(3H)- 0.25            Accept                                   
furanone                                                                  
______________________________________
The compounds of the present invention are active as anti-inflammatory agents.
The compounds were tested to determine their effect on conditions which result in inflammation by measuring the effect on ultraviolet induced erythema in guinea pigs. Albino guinea pigs were depilitated on their flanks, the evening before testing, with a standard mixture of barium sulfite and gum acacia. On the morning of the test, groups of 4 guinea pigs were dosed by gavage one hour (-1 hour) to ultraviolet exposure. At zero hour they were restrained in a plastic container which allows exposure of three circular spots. They were then exposed to ultraviolet irradiation from a "Hanovia" Kromayer lamp, model 10, for 60 seconds. At one and four hours the degree of erythema for each of the three sites was assessed according to the following scoring system.
0=no erythema
0.5=incomplete circle or faint erythema
1.0=complete circle of distinct erythema
Thus, the maximum score for each animal is 3.0. The results of this test on a typical compound of the present invention appears in Table II.
              TABLE II                                                    
______________________________________                                    
         Dose   No. of    Score (avg.)                                    
Compound   mg/kg    Animals   1 Hour 4 Hours                              
______________________________________                                    
5-(4-biphenyl-                                                            
yl)dihydro-2-                                                             
           250      8         0      2.1                                  
(3H)-furanone                                                             
______________________________________
DETAILED DESCRIPTION OF THE INVENTION
The particular embodiments of this invention are detailed in the following examples.
EXAMPLE 1 5-(4-Biphenylyl)dihydro-2(3H)-furanone
A 10.3 g. portion of 3-(4-biphenylylcarbonyl)propionic acid in 8 ml. of 6 N NaOH is treated with 15 g. of sodium borohydride and stirred for 2 hours. The cloudy solution is treated carefully over a 30 minute period with 25 ml. of glacial acetic acid producing a colorless precipitate. The solid is collected by filtration, washed with water and dried. A mixture of a 9 g. portion of this solid, 7.5 ml. of 6 N NaOH and 15 g. of sodium borohydride in 2 liters of water is stirred for 2 hours. The mixture is filtered and the filtrate is treated with glacial acetic acid giving 5 g. of 4-(4-biphenylyl)-4-hydroxybutyric acid.
A mixture of one g. of the above product, 75 ml. of warm (60° C.) glacial acetic acid and 0.25 ml. of H2 SO4 is stirred for 30 minutes and then neutralized with an excess of sodium acetate. An equal volume of water is added causing the precipitation of a solid which is collected giving 5-(4-biphenylyl)dihydro-2(3H)-furanone.
EXAMPLE 2 Dihydro-5-(4'-Hydroxy-4-biphenylyl)-2(3H)-furanone
A 3.4 g. portion of 4'-methoxy-γ-oxo-4-biphenylbutyric acid (U.S. Pat. No. 2,590,085), 25 ml. of glacial acetic acid and 7.5 ml. of hydrogen bromide are refluxed for 18 hours. The mixture is cooled in ice and then filtered, giving 2.9 g. of 4'-hydroxy-γ-oxo-biphenylbutyric acid.
A 2.0 g. portion of the above product is added to 320 ml. of water. A 10 ml. portion of 1 N NaOH is added. A 3 g. portion of sodium borohydride is added and the mixture is stirred at room temperature overnight. The mixture is cooled in ice and 12 ml. of glacial acetic acid is added. The gelatinous precipitate is filtered through diatomaceous earth and washed with ether. The ether is evaporated giving a solid which is treated with water and filtered, giving a solid. The solid is triturated with benzene and the solid is recovered. This solid is dissolved in a small amount of ethyl acetate, benzene is added and the mixture is stored overnight in a chill room. The solid is recovered by filtration and air dried. The mother liquor crop (0.45 g.) is refluxed overnight in 20 ml. of xylene giving a solid which is crystallized from ethanol treated with activated charcoal giving the final product, m.p. 176.5°-181° C.
EXAMPLE 3 cis-5-(4-Biphenylyl)dihydro-4-hydroxy-2 (3H)-furanone and trans-5-(4-Biphenylyl)dihydro-4-hydroxy-2(3H)-furanone
These two products are derived as metabolic products from dogs. Two adult beagles, one male (9.2 kg.) and one female (7.3 kg.) are used. The dogs are fed 300 g. of Rockland Dog Diet (Tekland Inc., Monmouth, Illinois) once a day and have free access to water. On the day of the test each dog receives a sigle oral dose (100 mg./kg.) of 14 C-3-(4-biphenylylcarbonyl)propionic acid sodium salt as a clear aqueous solution. The dogs were maintained individually in metabolism cages. Urine samples are collected as 24 hour cumulative samples in containers surrounded by dry ice, and stored in a deep freeze.
CHROMATOGRAPHY
The column support is acid washed and methanol rinsed Celite® No. 545. The column is 1.5×45 cm. The solvent system is heptane:ethyl acetate:methanol:water:acetic acid (300:200:80:20:1.5). A 20 g. portion of the Celite is mixed with 10 ml. of the lower phase of the solvent system. The column is packed with 0.5 g. increments of the wet column support after placing a glass wool plug in the bottom. The packed column is about 35 cm. long.
A 100 ml. sample of the cumulative 24 hour urine from the dogs is heated with 5 N hydrochloric acid for 30 minutes in a boiling water bath. After cooling, the solution is extracted with a mixture of chloroform:ether (8:3). The solvent extract is evaporated under nitrogen and the residue is mixed with 5.0 ml. of lower phase and 10 g. of Celite and charged on the column. The column is eluted with upper phase. Fractions of 7.0 ml are collected and radioactivity is measured in either a Beckman LS-250 Liquid Scintillation Spectrometer or a Nuclear-Chicago, Mark I Liquid Scintillation Spectrometer. The desired metabolites are located by thin-layer chromatography and identified by ultraviolet, mass spectrometer, nuclear magnetic resonance and infrared absorption patterns.
EXAMPLE 4 cis-5-(4-Biphenylyl)dihydro-3-hydroxy-2(3H)-furanone and trans-5-(4-Biphenylyl)dihydro-3-hydroxy-2(3H)-furanone
These two products are derived as metabolic products from guinea pigs. Nineteen normal guinea pigs from the Lederle colony are used. Their weight range is 290-340 g. The guinea pigs are fasted overnight before dosing. Drinking water and food are available throughout the test period. The guinea pigs receive a single oral dose of 100 mg. of 14 C-3-(4-biphenylylcarbonyl)propionic acid sodium salt per kg. of body weight, administered as a clear aqueous solution. The guinea pigs are maintained individually in metabolism cages. The urine samples are collected as 24 hour cumulative samples in containers surrounded by dry ice and then stored in a deep freeze.
The chromatography used is the same as described in Example 3. Radioactivity is measured as described in Example 3.
A 40 ml. combined sample of the cumulative 24 hour urine from the guinea pigs is heated with 20 ml. of 5N-hydrochloric acid for 45 minutes in a boiling water bath. The mixture is cooled and extracted three times with a mixture of chloroform:ether (8:3). The solvent is evaporated under nitrogen. The residue is mixed with 1.0 ml. of the lower phase of the solvent system and 2.0 g. of Celite. The column is eluted with upper phase. Fractions of 3.0 ml. are collected and measured for radioactivity. The desired metabolites are located by thin-layer chromatography and identified by mass spectrometer, nuclear magnetic resonance and infrared absorption patterns.
EXAMPLE 5 Preparation of Compressed Tablets 
______________________________________                                    
Ingredient            mg./Tablet                                          
______________________________________                                    
Active compound        0.5-250                                            
Dibasic calcium phosphate N.F.                                            
                      qs                                                  
Starch U.S.P.         20                                                  
Modified starch        5                                                  
Magnesium stearate U.S.P.                                                 
                      1-3                                                 
______________________________________
EXAMPLE 6 Preparation of Hard Shell Capsule 
______________________________________                                    
Ingredient            mg./Capsule                                         
______________________________________                                    
Active compound        0.5-250                                            
Lactose spray dried   qs                                                  
Magnesium stearate    1-5                                                 
______________________________________
EXAMPLE 7 Preparation of Oral Suspension 
______________________________________                                    
Ingredient            % W/V                                               
______________________________________                                    
Active compound           0.05-5                                          
Polysorbate 80 U.S.P.     0.1                                             
Flavoring Agent           qs                                              
Methylparaben U.S.P.      0.18                                            
Propylparaben U.S.P.      0.02                                            
Liquid sugar              75.0                                            
Purified Water   qs       100.00                                          
______________________________________
Other embodiments of this invention will be obvious to those skilled in the art without departing from the spirit of the invention. The foregoing examples are merely illustrative of the invention which is limited solely by the claims.

Claims (5)

I claim:
1. The compound, 5-(4'-hydroxy-4-biphenylyl)dihydro-2(3H)-furanone.
2. The compound cis-5-(4-biphenylyl)dihydro-3-hydroxy-2(3H)-furanone.
3. The compound trans-5-(4-biphenylyl)dihydro-3-hydroxy-2(3H)-furanone.
4. The compound cis-5-(4'-biphenylyl)dihydro-4-hydroxy-2(3H)-furanone.
5. The compound trans-5-(4-biphenylyl)dihydro-4-hydroxy-2(3H)-furanone.
US06/054,748 1979-07-05 1979-07-05 Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid Expired - Lifetime US4247466A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US06/054,748 US4247466A (en) 1979-07-05 1979-07-05 Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/054,748 US4247466A (en) 1979-07-05 1979-07-05 Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid

Publications (1)

Publication Number Publication Date
US4247466A true US4247466A (en) 1981-01-27

Family

ID=21993258

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/054,748 Expired - Lifetime US4247466A (en) 1979-07-05 1979-07-05 Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid

Country Status (1)

Country Link
US (1) US4247466A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483667A3 (en) * 1990-11-02 1992-09-16 Dr. Karl Thomae Gmbh Cyclic imino derivatives, process for their preparation and drugs containing them
US5455348A (en) * 1991-08-19 1995-10-03 Karl Thomae 2-pyrrolidinones, pharmaceutical compositions containing these compounds and processes for preparing them
US5854277A (en) * 1994-11-15 1998-12-29 Bayer Corporation Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US6166082A (en) * 1994-11-15 2000-12-26 Bayer Corporation Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US3859256A (en) * 1972-08-17 1975-01-07 Boehringer Sohn Ingelheim Halogenated 3-(4'-biphenylyl)-butanols
US3966978A (en) * 1975-04-25 1976-06-29 American Cyanamid Company 4-Biphenylacetic acid as an inhibitor of platelet aggregation
US3966960A (en) * 1975-04-25 1976-06-29 American Cyanamid Company 3-(4-Biphenylcarbonyl)propionic acid as an inhibitor of platelet aggregation
US3969402A (en) * 1972-06-15 1976-07-13 The Boots Company Limited Phenylalkanoic acids
US4021479A (en) * 1971-03-17 1977-05-03 Boehringer Ingelheim Gmbh Derivatives of 4-(4-biphenylyl)-butyric acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US4021479A (en) * 1971-03-17 1977-05-03 Boehringer Ingelheim Gmbh Derivatives of 4-(4-biphenylyl)-butyric acid
US3969402A (en) * 1972-06-15 1976-07-13 The Boots Company Limited Phenylalkanoic acids
US3859256A (en) * 1972-08-17 1975-01-07 Boehringer Sohn Ingelheim Halogenated 3-(4'-biphenylyl)-butanols
US3966978A (en) * 1975-04-25 1976-06-29 American Cyanamid Company 4-Biphenylacetic acid as an inhibitor of platelet aggregation
US3966960A (en) * 1975-04-25 1976-06-29 American Cyanamid Company 3-(4-Biphenylcarbonyl)propionic acid as an inhibitor of platelet aggregation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Genge et al., Chem. Abst., vol. 52, 9039 g. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483667A3 (en) * 1990-11-02 1992-09-16 Dr. Karl Thomae Gmbh Cyclic imino derivatives, process for their preparation and drugs containing them
US5541343A (en) * 1990-11-02 1996-07-30 Karl Thomae Gmbh Cyclic imino derivatives and pharmaceutical compositions containing them
US5591769A (en) * 1990-11-02 1997-01-07 Karl Thomae Gmbh Cyclic imino derivatives and pharmaceutical compositions containing them
US5455348A (en) * 1991-08-19 1995-10-03 Karl Thomae 2-pyrrolidinones, pharmaceutical compositions containing these compounds and processes for preparing them
US5861428A (en) * 1994-11-15 1999-01-19 Bayer Corporation Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitors
US5859047A (en) * 1994-11-15 1999-01-12 Bayer Corporation Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitors
US5854277A (en) * 1994-11-15 1998-12-29 Bayer Corporation Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors
US5861427A (en) * 1994-11-15 1999-01-19 Kluender; Harold Clinton Eugene Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitors
US5874473A (en) * 1994-11-15 1999-02-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US5886024A (en) * 1994-11-15 1999-03-23 Bayer Corporation Thiophene-containing butonic acid derivatives as matrix metalloprotease inhibitors
US5886043A (en) * 1994-11-15 1999-03-23 Bayer Corporation Substituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitors
US6166082A (en) * 1994-11-15 2000-12-26 Bayer Corporation Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors

Similar Documents

Publication Publication Date Title
EP0149242B1 (en) 1-(2-hydroxyaryl)-alcan-1-one oxime, preparation and pharmaceutical use
CS200455B2 (en) Method of producing derivatives of benzoxazole
US4526894A (en) Pharmaceutically active 4-hydroxy-3-benzoyl-2-quinolone derivatives
US4247466A (en) Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid
US3760084A (en) Method of using 5-amino-1-phenyl or substituted phenyl-4-pyrazolecarbonitriles or carbox-amides
US5747521A (en) N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and pharmaceutical preparation containing the same
US4279922A (en) Photosensitizing benzofuranacrylics
US4219668A (en) 4-Hydroxy,4-biphenylbutyric acid
US4315862A (en) Process for preparing cannabichromene
SU1083909A3 (en) Process for preparing 6-substituted derivatives of pyranone
US3872108A (en) Novel chromone derivatives and the production thereof
EP0564648B1 (en) Aconitine compound and analgesic/antiinflammatory agent
US4036983A (en) Ferrocene compounds and pharmaceutical composition for use in treatment of iron deficiency in an animal
US4367229A (en) 3-Substituted-tetrahydro-pyrrolo[1,2-a]pyrimidines and pharmaceutical compositions
US3248292A (en) Pharmaceutically active dimethoxyquinazolines
JPH0348906B2 (en)
US4260767A (en) 2-Pyridylhydrazides
US5204355A (en) 15-nitro-2β, 3β-dihydro- and 15-nitro-2β,3β,6,7-tetrahydrotabersonine derivatives, pharmaceutical compositions containing them and process for preparing same
DE2731662A1 (en) 5- (2-FUROYL) -, 5- (2-THENOYL) -, 5- (3-FUROYL) - AND 5- (3-THENOYL) -1,2- DIHYDRO-3H-PYRROLO- SQUARE CLIP ON 1, 2-ANGLE CLAMP FOR -PYRROL-1-CARBONIC ACID DERIVATIVES AND METHOD OF MANUFACTURING THE SAME
US4242330A (en) Derivative of aspirin
US4067983A (en) Pharmaceutical compositions and methods
US3864359A (en) 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and method of preparation thereof
US3987197A (en) 3-(2'-fluoro-4-biphenylyl)-butyric acid and salts thereof
NL8200491A (en) 17, 18-DEHYDROAPOVINCAMINOL-3'4 ', 5'-TRIMETHOXYBENZOATE, ITS ACID ADDITION SALTS, INTERMEDIATES, AND METHODS FOR PREPARING THESE COMPOUNDS.
US3821408A (en) Compositions of sulfonium ylides and method of use